News

Cabazitaxel versus Docetaxel Both With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (FIRSTANA)

Publish date: October 16, 2012

 

Objectives: Cabazitaxel (Jevtana) is approved for second-line treatment of metastatic prostate cancer in patients previously treated with docetaxel (Taxotere). This randomized phase III trial pits the two taxanes against each other in the first-line setting. Two doses of cabazitaxel (20 mg/m2 and 25 mg/m2) are explored; overall survival is the primary outcome.

Key entry or exclusion criteria: Patients with prior chemotherapy for prostate cancer are excluded.

Locations: 166 sites.

Goal: 1,170 patients.

Study sponsor: Sanofi-Aventis

Link for more information: clinicaltrials.gov/ct2/show/NCT01308567

NIH clinical trials identifier: NCT01308567

Recommended Reading

Safety and Efficacy Study of Enzalutamide versus Bicalutamide in Men With Prostate Cancer (STRIVE)
MDedge Hematology and Oncology
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Patients With High-Risk Localized Prostate Cancer
MDedge Hematology and Oncology
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Patients with High-Risk Prostate Cancer
MDedge Hematology and Oncology
Radiation Therapy With or Without Androgen-Deprivation Therapy in Patients with Prostate Cancer
MDedge Hematology and Oncology
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
MDedge Hematology and Oncology
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Patients with a Rising PSA after Surgery for Prostate Cancer
MDedge Hematology and Oncology
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
MDedge Hematology and Oncology
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1)
MDedge Hematology and Oncology
Study of Cabozantinib (XL184) Versus Mitoxantrone plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)
MDedge Hematology and Oncology
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men with Prostate Cancer (SYNERGY)
MDedge Hematology and Oncology